Table 4 Baseline descriptive statistics of the treatment subgroups with liver T2* value < 9.2 ms
P | Deferiprone group (n = 23) | Combined group (n = 41) | Deferoxamine group (n =33) | P | |
|---|---|---|---|---|---|
Age (yrs) | 0.376 | 30.6 ± 6.1 | 28.9 ± 6.2 | 30.3 ± 8.3 | 0.439 |
Male (%) | 0.108 | 69.6% | 48.8% | 51.5% | 0.815 |
Chel. starting age (yrs) | 0.548 | 5.1 ± 5.7 | 4.2 ± 4.3 | 5.4 ± 3.9 | 0.326 |
Ferritin (ng/l) | <0.0001 | 1347 ± 1782 | 2101 ± 944 | 1729 ± 1672 | 0.009 |
Liver T2* (ms) | 0.733 | 3.3 ± 2.1 | 3.6 ± 2.3 | 4.0 ± 2.0 | 0.272 |
MRI LIC (mg/g dry weight) | 0.940 | 12.5 ± 9.5 | 12.3 ± 10.2 | 9.6 ± 7.2 | 0.197 |